Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers.
Affiliation1 National Maternity Hospital, Holles Street, Dublin 2, Ireland. 2 UCD School of Medicine, National Maternity Hospital, Holles Street, Dublin 2, Ireland
Local subject classificationBIOMARKERS
MetadataShow full item record
CitationHelena C. Bartels, James D. Postle, Paul Downey, and Donal J. Brennan, “Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers,” Disease Markers, vol. 2018, Article ID 1507674, 11 pages, 2018. https://doi.org/10.1155/2018/1507674.
AbstractPlacenta accreta spectrum (PAS) is a condition of abnormal placental invasion encompassing placenta accreta, increta, and percreta and is a major cause of severe maternal morbidity and mortality. The diagnosis of a PAS is made on the basis of histopathologic examination and characterised by an absence of decidua and chorionic villi are seen to directly adjacent to myometrial fibres. The underlying molecular biology of PAS is a complex process that requires further research; for ease, we have divided these processes into angiogenesis, proliferation, and inflammation/invasion. A number of diagnostic serum biomarkers have been investigated in PAS, including human chorionic gonadotropin (HCG), pregnancy-associated plasma protein-A (PAPP-A), and alpha-fetoprotein (AFP). They have shown variable reliability and variability of measurement depending on gestational age at sampling. At present, a sensitive serum biomarker for invasive placentation remains elusive. In summary, there are a limited number of studies that have contributed to our understanding of the molecular biology of PAS, and additional biomarkers are needed to aid diagnosis and disease stratification.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States
- Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging.
- Authors: Jauniaux E, Collins S, Burton GJ
- Issue date: 2018 Jan
- Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta.
- Authors: Büke B, Akkaya H, Demir S, Sağol S, Şimşek D, Başol G, Barutçuoğlu B
- Issue date: 2018 Jan
- Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete.
- Authors: Zhou J, Li J, Yan P, Ye YH, Peng W, Wang S, Wang XT
- Issue date: 2014 Sep
- Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein.
- Authors: Zelop C, Nadel A, Frigoletto FD Jr, Pauker S, MacMillan M, Benacerraf BR
- Issue date: 1992 Oct
- Obstetrical complications associated with abnormal maternal serum markers analytes.
- Authors: Gagnon A, Wilson RD, SOCIETY OF OBSTETRICIANS AND GYNAECOLOGISTS OF CANADA GENETICS COMMITTEE.
- Issue date: 2008 Oct